tocilizumab
Pronunciation: toe-sil-IZ-oo-mab
A humanized monoclonal antibody targeting the interleukin-6 receptor, used in systemic juvenile idiopathic arthritis and other inflammatory conditions.
Full Definition
Tocilizumab is a humanized monoclonal antibody that binds to both soluble and membrane-bound interleukin-6 receptors, inhibiting IL-6-mediated signaling. It is particularly effective in systemic juvenile idiopathic arthritis, where IL-6 plays a central role in fever, growth retardation, and laboratory abnormalities. The medication can be administered intravenously every 2-4 weeks or subcutaneously weekly, with dosing based on body weight in children. Monitoring includes assessment for infection risk, neutropenia, liver enzyme elevations, and lipid abnormalities.
Usage
Usage note: Brand name Actemra should be capitalized; specify route of administration.
In Context
- "Tocilizumab therapy normalized the patient's inflammatory markers and resolved growth velocity concerns." — Long-term follow-up report
- "The transition from intravenous to subcutaneous tocilizumab improved treatment convenience for the adolescent patient." — Medication adjustment note